Pathology Doctors in Oregon City, OR Accepting Medicare

2 Pathology doctors found. Showing 1 - 2

Jay Mead, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Medicare Enrolled Practice Location: 616 Madison St # 100, Oregon City, OR 97045 Phone: 503-656-9596

Raymond C. Harry, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 1500 Division St, Oregon City, OR 97045 Phone: 503-650-6816    Fax: 503-557-2198

News Archive

Study finds link between severe sepsis and chronic diseases

It's a major cause of death, yet few of us have ever heard of it. Sepsis occurs when a patient's immune system overreacts to an infection, triggering a potentially fatal, system-wide inflammation. Severe sepsis strikes about 750,000 Americans each year, most of them older and often ill, with as many as half of these patients dying as septic shock shuts down their organs. Furthermore, patients in many Southern states are about twice as likely to develop sepsis for reasons unknown.

Intermountain signs collaborative research agreement with Myriad

Intermountain Healthcare and Myriad Genetics today announced they have signed a collaborative research agreement. The purpose of this agreement is to perform research and validation studies on transformative molecular diagnostic tests being developed by Myriad in an effort to improve the care and treatments for patients at Intermountain and around the world.

Study reveals surprising results that may impair future therapeutic approaches in TGF-beta pathway

Researchers at Helmholtz Zentrum München describe how breast cancer cells challenged with a small-molecule inhibitor targeting specific invasive properties switch to an alternative mode-of-action, rendering them even more aggressive. The results may impair future therapeutic approaches in the TGF-beta pathway and are published in the journal 'Oncotarget'.

Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million

Novo Nordisk has completed a pre-specified meta-analysis based on the Degludec phase 3a trial programme. The meta-analysis confirmed that Degludec is associated with a lower risk of hypoglycaemia compared to insulin glargine, both on the total number of confirmed hypoglycaemic events, and on the number of confirmed nocturnal hypoglycaemic events. Both findings are statistically significant.

Read more Medical News

› Verified 6 days ago